
Opinion|Videos|March 6, 2024
Future Direction for KRAS G12C NSCLC Management
Author(s)Hatim Husain, MD
Discuss emerging data and therapies to optimize future treatment.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Erica Stringer-Reasor on Gedatolisib's FDA Approval in Breast Cancer
2
Sonesitatug Vedotin Improves Survival in CLDN18.2-Positive Gastric Cancer
3
Phase 2 CHIMERA Trial Tests Neoadjuvant Pembrolizumab in Mesothelioma
4
Darlifarnib Plus Cabozantinib Shows Durable Activity in Advanced RCC
5





























